Literature DB >> 12464795

Current treatments for hepatitis.

Jean Fleming1.   

Abstract

Common viral agents known to cause inflammation of the liver (hepatitis) are hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Some other viral agents that can cause hepatitis are Epstein Barr virus, herpes simplex virus, and cytomegalovirus. Some patients infected with these viral agents progress to develop chronic viral hepatitis. Approximately 45% of chronic hepatitis cases are associated with hepatitis C and approximately 15% are associated with hepatitis B. In addition to being a leading cause of chronic hepatitis, HCV is most frequently associated with liver cirrhosis and hepatocellular carcinoma. Although much has been published about HAV and HBV, health professionals have learned about HCV only in recent years. For this reason, this article will emphasize the epidemiologic challenges and current treatments for hepatitis C; hepatitis A and B will be discussed in brief.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464795     DOI: 10.1097/00129804-200211000-00006

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  6 in total

1.  Effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca(2+) currents.

Authors:  Kun Liu; Yu-Hua Liao; Zhao-Hui Wang; Shu-Li Li; Ming Wang; Ling-Lan Zeng; Ming Tang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication.

Authors:  Jun Yi; Wei-Dong Gong; Ling Wang; Rui Ling; Jiang-Hao Chen; Jun Yun
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

3.  Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.

Authors:  Jian Ming Fan; Qiao Zhang; Jun Xu; Sha Zhu; Tao Ke; De Fu Gao; Yu Bao Xu
Journal:  Mol Biol Rep       Date:  2007-12-05       Impact factor: 2.316

4.  Anti-HBV activity of TRL mediated by recombinant adenovirus.

Authors:  Wei-Dong Gong; Ya Zhao; Jun Yi; Jin Ding; Jun Liu; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

5.  Inhibition of HBV targeted ribonuclease enhanced by introduction of linker.

Authors:  Wei-Dong Gong; Jun Liu; Jin Ding; Ya Zhao; Ying-Hui Li; Cai-Fang Xue
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

6.  Detection of anti-HAV antibody with dot immunogold filtration assay.

Authors:  Zhong-Jun Shao; De-Zhong Xu; Yong-Ping Yan; Jing-Hua Li; Jing-Xia Zhang; Zhi-Ying Zhang; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.